[Form 4] Nurix Therapeutics, Inc. Common stock Insider Trading Activity

Rhea-AI Filing Summary

Nurix Therapeutics (NRIX) – Form 4 insider activity (30-Jul-2025)

Chief Legal Officer Christine Ring converted a total of 10,532 restricted stock units into common shares through four mandatory “M” transactions at a $0 exercise price. To satisfy withholding taxes, she executed a single “S” sale of 3,841 shares at a weighted-average price of $12.011 (range: $11.78-$12.315). Net of the sale, Ms. Ring’s direct holdings increased by 6,691 shares to 44,009 shares.

Following the transactions, she still holds 31,442 unvested RSUs that will vest quarterly in equal installments under previously disclosed three- and four-year schedules. All transactions were structured, non-discretionary events: the conversions stem from scheduled RSU vesting, and the sale was a “sell-to-cover” mandated by the company’s equity plan. No open-market discretionary buying or selling occurred.

Positive

• Net increase of 6,691 shares by a senior officer signals greater equity alignment with shareholders.
• Remaining 31,442 RSUs provide future upside exposure, indicating long-term engagement.

Negative

• No discretionary open-market purchase; transactions were automatic, limiting the strength of the positive signal.

Insights

Financial Analyst

TL;DR: Officer net-adds 6.7k shares; sale only for taxes—mildly positive alignment signal.

The filing shows a routine vesting/settlement cycle rather than discretionary trading. The CLO increased her direct ownership by ~18%, moving from 37.3k to 44.0k shares while retaining 31.4k RSUs that provide further upside exposure. Because the 3,841-share sale was solely to cover withholding, it does not suggest profit-taking. Although the absolute dollar value (~$46k gross sale) is small relative to NRIX’s market cap, cumulative insider accumulation can be interpreted as a confidence indicator. No derivative option grants or unusual share disposals were disclosed. Overall impact is modestly positive for sentiment but not material for valuation.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

van Houte Hans

(Last) (First) (Middle)

C/O NURIX THERAPEUTICS, INC.

1700 OWENS STREET, SUITE 205

(Street)

SAN FRANCISCO CA 94158

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Nurix Therapeutics, Inc. [ NRIX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Financial Officer

3. Date of Earliest Transaction (Month/Day/Year)
07/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	07/30/2025		M		2,886	A	$0	36,610	D
Common Stock	07/30/2025		M		2,000	A	$0	38,610	D
Common Stock	07/30/2025		M		3,750	A	$0	42,360	D
Common Stock	07/30/2025		M		2,858	A	$0	45,218	D
Common Stock	07/30/2025		S(1)		4,304	D	$12.011(2)	40,914	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Units	$0(3)	07/30/2025		M			2,886	(4)	(5)	Common Stock	2,886	$0	5,773	D
Restricted Stock Units	$0(3)	07/30/2025		M			2,000	(6)	(5)	Common Stock	2,000	$0	6,000	D
Restricted Stock Units	$0(3)	07/30/2025		M			3,750	(7)	(5)	Common Stock	3,750	$0	26,250	D
Restricted Stock Units	$0(3)	07/30/2025		M			2,858	(8)	(5)	Common Stock	2,858	$0	31,442	D

Explanation of Responses:

1. The sales reported on this Form 4 represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of restricted stock units ("RSUs"). These sales are mandated by the Issuer's election under its equity incentive plans to require the satisfaction of tax withholding obligations to be funded by a "sell to cover" transaction and do not represent discretionary trades by the Reporting Person.

2. Represents the weighted average sale price. The lowest price at which shares were sold was $11.78 and the highest price at which shares were sold was $12.315. The Reporting Person undertakes to provide upon request to the staff of the Securities and Exchange Commission, the Issuer or its stockholders, full information regarding the total number of shares sold at each separate price within the range set forth herein.

3. Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's common stock.

4. The RSUs will vest in substantially equal increments quarterly over four years, with the first quarterly increment vesting on April 30, 2022, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's Common Stock will be delivered to the Reporting Person following vesting.

5. RSUs do not expire; they either vest or are canceled prior to the vest date.

6. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2023, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

7. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2024, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

8. The RSUs will vest as to 1/12 of the total award quarterly over three years, with the first quarterly increment vesting on July 30, 2025, subject to the Reporting Person's provision of services to the Issuer on each vesting date. Shares of the Issuer's common stock will be delivered to the Reporting Person following vesting.

Remarks:

	/s/ Daniel Burbach, as Attorney-in-Fact for Hans van Houte	07/30/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

How many NRIX shares did the insider acquire on 30-Jul-2025?

Christine Ring acquired 10,532 shares through RSU vesting conversions.

Why were 3,841 NRIX shares sold?

They were sold to cover tax-withholding obligations required by the company’s equity plan.

What is the insider’s total NRIX holding after the transactions?

Direct ownership increased to 44,009 common shares plus 31,442 unvested RSUs.

At what price were the shares sold?

The weighted-average sale price was $12.011, with a low of $11.78 and a high of $12.315.

Do the RSUs reported in Table II expire?

No. RSUs do not expire; they either vest or are cancelled if service conditions are not met.